MA29167B1 - Sels de cinnamate d'un agoniste beta-2-adrenergique - Google Patents

Sels de cinnamate d'un agoniste beta-2-adrenergique

Info

Publication number
MA29167B1
MA29167B1 MA30100A MA30100A MA29167B1 MA 29167 B1 MA29167 B1 MA 29167B1 MA 30100 A MA30100 A MA 30100A MA 30100 A MA30100 A MA 30100A MA 29167 B1 MA29167 B1 MA 29167B1
Authority
MA
Morocco
Prior art keywords
beta
adrenergic agonist
cinnamate salts
cinnamate
salts
Prior art date
Application number
MA30100A
Other languages
English (en)
French (fr)
Inventor
Lois Elizabeth Vernon
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0500513A external-priority patent/GB0500513D0/en
Priority claimed from GB0514199A external-priority patent/GB0514199D0/en
Priority claimed from GB0514200A external-priority patent/GB0514200D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA29167B1 publication Critical patent/MA29167B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Golf Clubs (AREA)
  • Quinoline Compounds (AREA)
MA30100A 2005-01-11 2007-07-26 Sels de cinnamate d'un agoniste beta-2-adrenergique MA29167B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US64284405P 2005-01-11 2005-01-11
GB0500513A GB0500513D0 (en) 2005-01-11 2005-01-11 Novel compounds
GB0514199A GB0514199D0 (en) 2005-07-11 2005-07-11 Novel compounds
GB0514200A GB0514200D0 (en) 2005-07-11 2005-07-11 Novel compounds

Publications (1)

Publication Number Publication Date
MA29167B1 true MA29167B1 (fr) 2008-01-02

Family

ID=36046933

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30100A MA29167B1 (fr) 2005-01-11 2007-07-26 Sels de cinnamate d'un agoniste beta-2-adrenergique

Country Status (15)

Country Link
US (2) US7772250B2 (OSRAM)
EP (1) EP1846374A1 (OSRAM)
JP (1) JP2008526805A (OSRAM)
KR (1) KR20070097106A (OSRAM)
CN (1) CN101137625A (OSRAM)
AU (1) AU2006205933A1 (OSRAM)
BR (1) BRPI0606712A2 (OSRAM)
CA (1) CA2594484A1 (OSRAM)
EA (1) EA200701260A1 (OSRAM)
IL (1) IL184246A0 (OSRAM)
MA (1) MA29167B1 (OSRAM)
MX (1) MX2007008459A (OSRAM)
NO (1) NO20073282L (OSRAM)
NZ (1) NZ556335A (OSRAM)
WO (1) WO2006074897A1 (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006074897A1 (en) * 2005-01-11 2006-07-20 Glaxo Group Limited Cinnamate salts of a beta-2 adrenergic agonist
TW200738658A (en) 2005-08-09 2007-10-16 Astrazeneca Ab Novel compounds
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
TW200745067A (en) 2006-03-14 2007-12-16 Astrazeneca Ab Novel compounds
EP2064174B1 (en) 2006-08-10 2016-10-26 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Preparation of (r,r)- or (r,s)-fenoterol analogues and their use in treating congestive heart failure
TW200833670A (en) 2006-12-20 2008-08-16 Astrazeneca Ab Novel compounds 569
GB0702458D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab Salts 668
EP2231642B1 (en) 2008-01-11 2013-10-23 Novartis AG Pyrimidines as kinase inhibitors
WO2009154557A1 (en) 2008-06-18 2009-12-23 Astrazeneca Ab Benzoxazinone derivatives acting as beta2-adrenoreceptor agonist for the treatment of respiratory disorders
JP5837890B2 (ja) 2010-03-10 2015-12-24 アメリカ合衆国 神経膠芽腫および星状細胞腫の治療におけるフェノテロールおよびフェノテロール類似体の使用
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
AU2012220572A1 (en) 2011-02-25 2013-08-29 Irm Llc Compounds and compositions as trk inhibitors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US694568A (en) * 1901-01-03 1902-03-04 James W Mccarthy Yarn or thread guide for spinning-machines.
US4353656A (en) * 1980-10-14 1982-10-12 Xerox Corporation Moving coil, multiple energy print hammer system including a closed loop servo
US4778054A (en) * 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
EP0211595B1 (en) * 1985-07-30 1991-11-13 Glaxo Group Limited Devices for administering medicaments to patients
GB9004781D0 (en) * 1990-03-02 1990-04-25 Glaxo Group Ltd Device
HU225869B1 (en) * 1992-04-02 2007-11-28 Smithkline Beecham Corp Compounds with antiallergic and antiinflammatory activity and pharmaceutical compns. contg. them
US5998428A (en) * 1995-05-31 1999-12-07 Smithkline Beecham Corporation Compounds and methods for treating PDE IV-related diseases
GB9700226D0 (en) * 1997-01-08 1997-02-26 Glaxo Group Ltd Inhalation device
US6632666B2 (en) * 2000-01-14 2003-10-14 Biolife Solutions, Inc. Normothermic, hypothermic and cryopreservation maintenance and storage of cells, tissues and organs in gel-based media
US6653323B2 (en) 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
TWI249515B (en) * 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
US20030229058A1 (en) 2001-11-13 2003-12-11 Moran Edmund J. Aryl aniline beta2 adrenergic receptor agonists
EP1622875B1 (en) 2003-05-08 2009-12-02 Theravance, Inc. Crystalline forms of an arylaniline beta-2 adrenergic receptor agonist
TW200526547A (en) 2003-09-22 2005-08-16 Theravance Inc Amino-substituted ethylamino β2 adrenergic receptor agonists
TW200531692A (en) * 2004-01-12 2005-10-01 Theravance Inc Aryl aniline derivatives as β2 adrenergic receptor agonists
US7317023B2 (en) * 2004-07-21 2008-01-08 Theravance, Inc. Diaryl ether β2 adrenergic receptor agonists
WO2006074897A1 (en) * 2005-01-11 2006-07-20 Glaxo Group Limited Cinnamate salts of a beta-2 adrenergic agonist

Also Published As

Publication number Publication date
US7772250B2 (en) 2010-08-10
EP1846374A1 (en) 2007-10-24
EA200701260A1 (ru) 2008-02-28
CN101137625A (zh) 2008-03-05
CA2594484A1 (en) 2006-07-20
MX2007008459A (es) 2007-07-25
NZ556335A (en) 2009-07-31
NO20073282L (no) 2007-09-04
KR20070097106A (ko) 2007-10-02
US20080125462A1 (en) 2008-05-29
JP2008526805A (ja) 2008-07-24
IL184246A0 (en) 2007-10-31
AU2006205933A1 (en) 2006-07-20
BRPI0606712A2 (pt) 2010-03-16
US20060189654A1 (en) 2006-08-24
WO2006074897A1 (en) 2006-07-20

Similar Documents

Publication Publication Date Title
EP1938485A4 (en) REAL-PEER-TO-PEER NETWORK
EP2089845A4 (en) IDENTIFYING ATTRACTIONS FOR ONE PLACE
EP2123158A4 (en) HERBICIDE COMPOSITION
ITUD20060182A1 (it) "metodo di perforazione"
EP1735703A4 (en) CONTROL OF THE TASK VERSION
EP2083885A4 (en) KLINKENSTRUKTUREN AS NEEDLE PROTECTION
EP1938194A4 (en) EMBEDDED EEPROM ARRAY TECHNIQUES FOR HIGHER DENSITY
EP1997042A4 (en) SEARCH WITHIN ONE SITE OF A SEARCH RESULT
BRPI0819395A2 (pt) "ferramenta de limpeza"
IL184246A0 (en) Cinnamate salts of a beta -2 adrenergic agonist
EP1839669A4 (en) NEW ANGIOGENESEHEMMER
EP1938530A4 (en) MULTICASTING ARCHITECTURE AT APPLICATION LEVEL
EP2020231A4 (en) FAT ABSORPTION INHIBITORS
ITPN20050014A1 (it) "piedino livellatore perfezionato"
DE60231662D1 (de) Ung eines ultraschallbündels
EP1751557A4 (en) FLEXIBLE MICRO-SWITCHING PLACE TRANSFORMER MODULE
EP2064178A4 (en) PRODRUGS OF INHIBITORS OF CATHEPSIN S
EP1848790A4 (en) SEMICONDUCTOR CLEANING
EP1906972A4 (en) LPA2 RECEPTOR AGONIST HEMMER FROM CFTR
EP1898940A4 (en) Alpha2beta1 / GPIa IIA INTEGRIN INHIBITORS
EP1994591A4 (en) LOCAL CARBON DIOXIDE GENERATOR
EP1857104A4 (en) USE OF A CINNAMOYL COMPOUND
EP1848420A4 (en) POLYMORPH SHAPES OF A GABAA AGONIST
ITPN20050026A1 (it) "apparecchio di raffreddamento a funzionamento adattativo"
EP2076611A4 (en) MN / CA9 SPLICE VARIANTS